Since the identification of the oncogenic transforming role of germline RET mutations in hereditary MTC almost 30 years ago, the genetic landscape of thyroid cancer has been studied extensively resulting in the identification of attractive molecular targets for small-molecule kinase inhibitors, reviewed elsewhere (20). The gene discussed is RET; the disease is thyroid cancer.